8-K: Genprex Announces First Patient Dosed in Phase 2 Expansion of Acclaim-3 Lung Cancer Trial

Genprex has dosed the first patient in the Phase 2 expansion of its Acclaim-3 clinical trial, evaluating Reqorsa gene therapy with Tecentriq for advanced small cell lung cancer.

Summary

• Genprex has initiated the Phase 2 expansion of its Acclaim-3 clinical trial, which is testing Reqorsa gene therapy in combination with Tecentriq for patients with extensive stage small cell lung cancer (ES-SCLC).
• The first patient has been enrolled and dosed in this phase of the trial.
• The Phase 1 dose escalation portion of the trial was completed in December 2024, with the Safety Review Committee (SRC) approving the move to Phase 2.
• The Recommended Phase 2 Dose of REQORSA is set at 0.12 mg/kg, the highest dose level used in Phase 1, based on full safety data showing no dose-limiting toxicities.
• The Phase 2 expansion aims to enroll 50 patients across 10 to 15 U.S. sites.
• Patients will receive treatment with REQORSA and Tecentriq until disease progression or unacceptable toxicity.
• The primary goal of Phase 2 is to determine the 18-week progression-free survival rate.
• An interim analysis will be conducted after 25 patients have reached 18 weeks of follow-up.
• The company anticipates completing enrollment of the first 25 patients for the interim analysis in the second half of 2025.
• The Acclaim-3 trial has received FDA Fast Track and Orphan Drug Designations.

Sentiment

Score: 7

Explanation: The document is positive due to the advancement of the clinical trial to Phase 2 and the lack of dose-limiting toxicities in Phase 1. However, the inherent risks of clinical trials and the company's financial situation temper the overall sentiment.

Positives

• The initiation of the Phase 2 expansion of the Acclaim-3 trial is a positive step in the development of Reqorsa.
• The safety data from Phase 1 showed no dose-limiting toxicities, allowing for the use of the highest dose level in Phase 2.
• The FDA Fast Track and Orphan Drug Designations for the Acclaim-3 trial could expedite the regulatory process.
• The trial is targeting a significant unmet need in ES-SCLC patients who have progressed after initial treatment.

Risks

• The success of the clinical trial is not guaranteed, and results may not meet expectations.
• The company's ability to advance the clinical development, manufacturing, and commercialization of its product candidates is subject to risks and uncertainties.
• The company's ability to maintain compliance with Nasdaq listing requirements and to obtain capital to meet its long-term liquidity needs is not guaranteed.
• The company's reliance on third-party vendors, suppliers, and manufacturers carries risks related to their performance and ability to scale up production.
• The company's intellectual property and licenses are subject to risks.

Future Outlook

The company expects to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study in the second half of 2025.

Industry Context

This announcement is relevant to the oncology and gene therapy sectors, as it represents progress in the development of a novel treatment for a difficult-to-treat cancer. The combination therapy approach is also a growing trend in cancer treatment.

Comparison to Industry Standards

• The use of a combination therapy approach, combining a gene therapy (Reqorsa) with an immune checkpoint inhibitor (Tecentriq), is consistent with current trends in cancer treatment.
• Other companies are also exploring similar combination therapies for lung cancer, such as Bristol Myers Squibb with Opdivo and Yervoy, and Merck with Keytruda and chemotherapy.
• The 18-week progression-free survival rate is a common endpoint in lung cancer clinical trials, making the results comparable to other studies.
• The FDA Fast Track and Orphan Drug Designations are also common for drugs targeting unmet medical needs, indicating the potential significance of this therapy.

Stakeholder Impact

• Shareholders may view this as a positive development, potentially increasing the value of the company.
• Patients with ES-SCLC may benefit from a new treatment option.
• Employees of Genprex are likely to be positively impacted by the progress of the clinical trial.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• Enrollment of 50 patients in the Phase 2 expansion of the Acclaim-3 trial.
• Treatment of patients with REQORSA and Tecentriq until disease progression or unacceptable toxicity.
• Performance of an interim analysis after 25 patients reach 18 weeks of follow-up.
• Completion of enrollment of the first 25 patients for interim analysis in the second half of 2025.

Key Dates

Keywords

Reqorsa, Genprex, Acclaim-3, Small Cell Lung Cancer, ES-SCLC, Gene Therapy, Tecentriq, Clinical Trial, FDA Fast Track, Orphan Drug Designation